Drugs in MeSH Category GABA-B Receptor Agonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rubicon Research	BACLOFEN	baclofen	SOLUTION;ORAL	214445-001	Dec 6, 2024		RX	No	No
Ivax Sub Teva Pharms	BACLOFEN	baclofen	TABLET;ORAL	072234-001	Jul 21, 1988	AB	RX	No	No
Sun Pharm Inds Inc	BACLOFEN	baclofen	TABLET;ORAL	077862-002	Aug 14, 2006		DISCN	No	No
Amneal	BACLOFEN	baclofen	INJECTABLE;INTRATHECAL	091193-001	May 3, 2016	AP	RX	No	No
Unichem	BACLOFEN	baclofen	TABLET;ORAL	212067-002	Jul 9, 2020	AB	RX	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: GABA-B Receptor Agonists

Last updated: April 24, 2026

What defines the GABA-B receptor agonist MeSH market segment?

NLM MeSH groups “GABA-B Receptor Agonists” as small molecules and related agents that activate the GABA-B receptor. The clinical and commercial center of gravity sits in central nervous system (CNS) disorders where GABA-B agonism is used for seizure control, muscle spasticity, and pain signaling modulation. The commercial set includes both established brands and pipeline programs using the same pharmacology, with the patent landscape dominated by compound claims plus method-of-treatment claims tied to epilepsy, spasticity, and neuropathic pain indications.

MeSH anchor concept: GABA-B receptor agonists. (MeSH) [1]

---

Which products and clinical categories drive demand now?

The GABA-B receptor agonist segment is not a single-asset market. It is an “engine” category used in MeSH indexing and R&D targeting, so market dynamics depend on which individual drug class is monetizing at a given time. Demand is typically indication-driven, with reimbursement linked to neurologic diagnosis coding and guideline adoption.

Current commercial and near-commercial anchors (by pharmacology)

Below are the market-relevant GABA-B agonist assets that most often surface in commercial and patent discussions for this class:

• Baclofen (GABA-B agonist)
  Indications commonly tied to spasticity management (systemic and intrathecal delivery in some settings).
• Gabapentinoid-adjacent CNS competitors are not the same class
  They act on calcium channels rather than GABA-B receptors; they compete in pain and neuropathic indications but are not GABA-B agonists and do not define this MeSH category.
• Baclofen derivatives and prodrugs (R&D and patenting trend)
  Patent activity clusters around improved CNS exposure, formulation, and sustained delivery.
• Investigational GABA-B agonists
  Pipeline work often targets improved selectivity, PK/PD, or tolerability and pairs with pain and CNS comorbidity profiles.

MeSH category definition: “GABA-B receptor agonists.” [1]

---

How do market dynamics shape pricing, access, and formulary outcomes?

1) Indication mix controls unit economics

GABA-B agonists monetize primarily where spasticity and seizure-related pathways justify long-term therapy. That produces two downstream commercial effects:

• Shorter “drug-journey” for established agents (formulary acceptance is tied to entrenched dosing regimens).
• Higher medical-claims scrutiny for new entrants that must beat baclofen-like comparators on spasticity burden, tolerability, and discontinuation rates.

2) CNS safety profile is the binding constraint

GABA-B agonists carry recognizable CNS adverse events (sedation, dizziness, coordination impairment). That shifts:

• Titration design (slower titration reduces discontinuation)
• Formulation selection (sustained release and intrathecal delivery strategies)
• Adherence and persistence (persistence is often a bigger driver than initial response)

3) Delivery modality is a competitive lever

Market competition is often less about receptor activation and more about how the drug reaches the CNS:

• Oral systemic exposure versus intrathecal administration
• Sustained-release platforms
• Combinations designed to reduce dosing frequency

4) Payor behavior favors predictable cost-per-day and reduced monitoring burden

For spasticity, durable cost-control requires:

• Low discontinuation
• Manageable adverse event rates
• Minimal laboratory or imaging requirements Those constraints reward incremental improvements that reduce total healthcare utilization.

---

What does the patent landscape look like for this MeSH class?

Patent structure typical for GABA-B agonists

Across this category, patents usually cluster into four buckets:

1. Compound claims
   • Core active agent structure
   • Salts, solvates, polymorphs
   • Stereoisomers or prodrugs
2. Formulation claims
   • Controlled-release matrices
   • Intrathecal-compatible compositions
   • Improved bioavailability compositions
3. Method-of-use claims
   • Spasticity treatment regimens
   • Seizure-related indications
   • Neuropathic pain and related syndromes
4. Combination claims
   • Add-on therapies with standard-of-care agents in epilepsy or pain settings

Legal and term mechanics that matter commercially

• Primary expiry: most compound patents expire 20 years from filing, subject to jurisdiction-specific adjustments.
• Patent term extension (PTE) and pediatric extensions: apply in many jurisdictions for eligible drugs; this often stretches “market exclusivity” window for commercial incumbents.
• Evergreening via formulation and method claims: sustained release, salt/polymorph, and specific dosing regimens frequently extend revenue before biosimilar-like competition emerges (not relevant for small molecules directly, but the “freedom-to-operate buffer” is similar).

---

Where are the highest-value claim positions in GABA-B agonists?

Compound + formulation is the highest-value pairing

For GABA-B agonists, the value chain often sits at the intersection of:

• Medicinal chemistry improvements (compound novelty)
• Exposure control (formulation IP)

This pairing lowers generic substitution risk by locking in:

• Physicochemical variants (salt/polymorph)
• Release profiles and dosing schedules

Method-of-use claims can carry late-stage leverage

Even when the core compound is close to expiry, method-of-treatment claims tied to:

• Specific spasticity subtypes
• Seizure phenotypes and dosing paradigms
• Pain responder profiles can keep a product protected and support payer negotiations through “approved use” anchoring.

---

How does this category’s patent timing map to a standard 5-year pharma cycle?

A practical way investors and R&D leaders track this segment is by aligning corporate milestones with typical patent-life events:

• 0-2 years post-asset launch: heavy filings around formulation and initial method claims; life-cycle events set up future jurisdictional enforcement.
• 2-5 years: new clinical data expands label; correspondingly, method claims broaden to match guideline usage.
• 3-7 years pre-expiry: defensive filings target obvious design-around paths, including next-gen release platforms and alternative salts/prodrugs.

The segment behaves like a “life-cycle extension” category because generic risk accelerates when compound claims expire and label claims become easy to copy.

---

What is the competitive intensity likely to look like?

Generic and “design-around” risk rises as compound coverage narrows

As compound patents near expiry, the competitive battlefield shifts to:

• Controlled-release/formulation substitutes
• Claim circumvention in dosing and use patterns
• Indication carve-outs that remain protected by method claims

Differentiation favors sustained delivery and tolerability improvements

Because receptor activation is pharmacologically shared, differentiation is often:

• PK improvement (CNS exposure consistency)
• Adverse event reduction (sedation and dizziness)
• Adherence gains (less frequent dosing)

These are the areas most likely to produce patentable formulation claims that remain enforceable after the compound falls out of exclusivity.

---

How do R&D targets in this class align with patenting trends?

Pipeline sponsors typically target one of three R&D outcomes that also create patentable matter:

1. Better CNS exposure
   • Prodrugs, solubility improvements, permeability enhancements
2. Improved tolerability
   • Dosing regimens, release-rate control, or alternative chemical forms
3. Expanded and narrower indication positioning
   • Method-of-use filings for specific subpopulations, dosing schedules, or disease states

These are the same pathways that reduce generic substitution and preserve net price.

---

What are the key MeSH and taxonomy implications for market sizing?

MeSH category membership does not automatically equal “approved products in every jurisdiction.” It is an ontology used for indexing medical literature. For market sizing, this matters because:

• Some assets may appear in the literature due to clinical trial activity.
• Some “GABA-B agonist” compounds may be repurposed outside traditional spasticity or seizure indications.
• Some pipeline assets may not reach commercialization despite generating patent filings.

Still, MeSH grouping is useful for scoping patent watchlists by mechanism rather than by a narrow drug list. MeSH defines the group concept “GABA-B receptor agonists.” [1]

---

Key Takeaways

• The GABA-B receptor agonist MeSH segment is indication-driven, with commercialization most often anchored in spasticity and CNS symptom control.
• Patent value concentrates in compound claims paired with formulation and controlled-release IP, plus method-of-use claims aligned to dosing and clinical subtypes.
• Market dynamics reward tolerability, CNS exposure consistency, and delivery modality because they influence discontinuation, adherence, and payer acceptance.
• Competitive pressure increases as compound coverage narrows, so defensive lifecycle strategy typically targets salts/polymorphs, prodrugs, and regimen-specific method claims.

---

FAQs

1. Is the MeSH category limited to baclofen?
   No. “GABA-B receptor agonists” is a mechanism-based category that includes multiple agents and related medicinal chemistry variants used across CNS indications. [1]

2. What patent claim type usually extends revenue the longest for GABA-B agonists?
   Formulation and method-of-use claims aligned to dosing schedules and delivery modality often provide late-stage protection and reduced generic substitution risk, even as core compound claims approach expiry.

3. Do GABA-B agonists compete mainly with each other or with broader CNS drugs?
   They compete both internally (within the mechanism category) and externally with CNS therapies in epilepsy, pain, and spasticity care pathways, but reimbursement and prescribing patterns are usually indication-anchored.

4. What is the main “non-mechanism” differentiator in this market?
   Delivery modality and tolerability, including sustained release and CNS exposure control, because receptor activation is shared across the category.

5. How should investors build a watchlist for this space?
   Use mechanism scoping via MeSH “GABA-B receptor agonists,” then add defensive categories most likely to carry enforceable value: salts/polymorphs, controlled-release formulations, prodrugs, and regimen-specific method claims. [1]

---

References

[1] U.S. National Library of Medicine. (n.d.). GABA-B Receptor Agonists (MeSH). MeSH Database. https://meshb.nlm.nih.gov/ (search result for “GABA-B Receptor Agonists”)